Genmab Portfolio Prioritization Update
29/12 14:11
Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher ‑ impact opportunities across Genmab’s late ‑ stage pipeline and increasingly competitive landscape This decision does not impact Genmab’s full ‑...